PT  - JOURNAL ARTICLE
AU  - Aatresh, Aishani V.
AU  - Cummings, Kate
AU  - Gerstein, Hilary
AU  - Knight, Christopher S.
AU  - Limberopolous, Andreas
AU  - Stasi, Megan A.
AU  - Bedugnis, Alice
AU  - Somberg, Kenneth A.
AU  - França, Camila T.
AU  - Mina, Michael J.
TI  - Development of at-home sample collection logistics for large scale SARS-CoV-2 seroprevalence studies
AID  - 10.1101/2021.01.14.21249824
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.14.21249824
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.14.21249824.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.14.21249824.full
AB  - In the midst of a pandemic, serologic studies are a valuable tool to understand the course of the outbreak and guide public health and general pandemic management. However, given significant safety constraints including social distancing and stay-at-home orders, sample collection becomes more difficult given traditional phlebotomy protocols. For such studies, a representative sample of the underlying population is paramount to elicit meaningful insights that capture the spread of the infection, particularly when different sub-populations face varying disease burden. We aimed to address these challenges by conducting a fully remote study to investigate the seroprevalence of SARS-CoV-2 in the state of Massachusetts. Leveraging electronic study engagement and at-home self-collection of finger-prick samples, we enrolled 2,066 participants representative of the ethnic and racial composition of Massachusetts. SARS-CoV-2 total IgG seropositivity was 3.15%, and follow-up measurements at days 7, 15, 45, and 90 indicate a generally durable antibody response. A higher risk of infection was observed for healthcare workers and their cohabitants and those with comorbidities, as well as lower-income, less educated, Hispanic, and those in the age groups of 18-29 and 50-59-years-old. High engagement and positive feedback from the participants and quality of self-collected specimens point to the usefulness of this design for future population-level serological studies that more effectively and safely reach a broad representative cohort, thus yielding more comprehensive insights into the burden of infection and disease in populations.Question We aimed to implement a fully remote seroprevalence study for SARS-CoV-2, leveraging electronic methods and at-home self-collection of specimens to engage a representative study population.Findings The population enrolled reflected the ethnic and racial composition of Massachusetts, revealing a SARS-CoV-2 seroprevalence of 3.15% and higher risk of previous infection associated with healthcare workers/their cohabitants, those with comorbidities, lower-income, less educated, Hispanic, and those in age groups 18-29 and 50-59 years old.Meaning High engagement and positive feedback from participants as well as quality of self-collected specimens point to the usefulness of this design for future population-level serological studies.Competing Interest StatementKate Cummings, Hilary Gerstein, Christopher S. Knight, Andreas Limberopolous, Megan A. Stasi and Kenneth A. Somberg are employees of TrialSpark, Inc. Funding StatementThis study was funded by Open Research. Michael J. Mina is supported by the NIH Directors Early Independence Award DP5OD028145.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was obtained from Advarra (Pro00043729) and the Harvard T.H. Chan School of Public Health review board (IRB20-1511). Written informed consent was obtained electronically from all participants prior to enrollment in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData has not been made publicly available to avoid compromising participant privacy or violating the ethical agreement in the informed consent forms. Data is available upon reasonable request by contacting Michael J. Mina.ACE2angiotensin-converting enzyme-2CAPCollege of American PathologistsCLIAClinical Laboratory Improvement AmendmentsCOVID-19coronavirus disease 2019ELISAenzyme-linked immunoassayEUAEmergency Use AuthorizationFDAFood and Drug AdministrationIgGimmunoglobulin GPPEpersonal protective equipmentRBDreceptor binding domainRT-PCRreverse transcriptase polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2SARSsevere acute respiratory syndromeUSPSUnited States Postal Service